clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-308Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYКомплаенс больных, получающих гиполипидемическую терапиюГуревичК. Г.clinvest@mail.ruБелоусовЮ. Б.clinvest@mail.ruФГБОУ ВО МГМСУ им. А.И. Евдокимова Минздрава России, г. МоскваRussian FederationГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», МоскваRussian Federation200426062018016772Copyright © Гуревич К.Г., Белоусов Ю.Б., 20182018Гуревич К.Г., Белоусов Ю.Б.Гуревич К.Г., Белоусов Ю.Б.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/308комплаенсприверженность лечениюстатиныгиполипидемическая терапияReferencesInsull W. J Inter Med 1997; 241 (4): 317-25.Insull W. J Inter Med 1997; 241 (4): 317-25.McCarthy R. Business Health 1998; 16: 27-33.McCarthy R. Business Health 1998; 16: 27-33.Shepherd J. et al. N Engl J Med 1995; 333(2): 1301-7.Shepherd J. et al. N Engl J Med 1995; 333(2): 1301-7.Urquhart J. et al. Pharmacoeconomics 1999; 15(3):217-28.Urquhart J. et al. Pharmacoeconomics 1999; 15(3):217-28.Lipids Research Clinic Program. JAMA 1994.Lipids Research Clinic Program. JAMA 1994.Coronary Drug Project Research Group. N Engl J Med 1980; 303 (18):1038-41.Coronary Drug Project Research Group. N Engl J Med 1980; 303 (18):1038-41.McKenney J.M. Am J Managed Care; 6 (19 Suppl ): S997-S1007.McKenney J.M. Am J Managed Care; 6 (19 Suppl ): S997-S1007.Kiortsis DN et al. J Clin Pharm Ther 2000; 25 (6): 445-51.Kiortsis DN et al. J Clin Pharm Ther 2000; 25 (6): 445-51.Frick M.N. et al. N Engl J Med 1987;317:1237-45.Frick M.N. et al. N Engl J Med 1987;317:1237-45.Mс Cormick L.S. et al. Am J Cardiol 1997; 80(9); 1130-3.Mс Cormick L.S. et al. Am J Cardiol 1997; 80(9); 1130-3.Lancet 1994;344:1383-9.Lancet 1994;344:1383-9.Sacks F.M. et al. N Engl J Med 1996;335;1001-9.Sacks F.M. et al. N Engl J Med 1996;335;1001-9.Shepherd J. et al. N Engl J Med 1995;333:1301-7.Shepherd J. et al. N Engl J Med 1995;333:1301-7.Downs J.R .et al. JAMA 1998;279:1615-22.Downs J.R .et al. JAMA 1998;279:1615-22.Arch Intern Med 1993; 153(9): 1079-87.Arch Intern Med 1993; 153(9): 1079-87.Gengo F.F. et al. Clin Cardiol 1995:18 (4):209-14.Gengo F.F. et al. Clin Cardiol 1995:18 (4):209-14.Boccuzi S.J. et al. Am J Cardiol 1991;68 (11):1127-31.Boccuzi S.J. et al. Am J Cardiol 1991;68 (11):1127-31.Peters Т.К., Muratti E.N., Mehra M. Am J Med 1994:96 (6A): 79S-83S.Peters Т.К., Muratti E.N., Mehra M. Am J Med 1994:96 (6A): 79S-83S.Jocubaitis L.A. Am J Cardiol 1994;73 (14):18D-24D.Jocubaitis L.A. Am J Cardiol 1994;73 (14):18D-24D.Davidson J. et al. Am J Cardiol 1998:82 (4B):32J-9J.Davidson J. et al. Am J Cardiol 1998:82 (4B):32J-9J.Santinga J.T. et al. Am J Med 1994:96(6): 509-15.Santinga J.T. et al. Am J Med 1994:96(6): 509-15.Raskin P. et al. Am J Med 1995:99 (4):362-9.Raskin P. et al. Am J Med 1995:99 (4):362-9.Davignon J. et al. Am J Cardiol 1994:73 (5):339-45.Davignon J. et al. Am J Cardiol 1994:73 (5):339-45.Wilclund O. et al.. Am J Med 1993:94 (1): 13-20.Wilclund O. et al.. Am J Med 1993:94 (1): 13-20.Black D.M., Bakker4Arkema R.G., Nawrocki J.W. Arch Intern Med 1998;158(6):577-84.Black D.M., Bakker4Arkema R.G., Nawrocki J.W. Arch Intern Med 1998;158(6):577-84.Gerson R.J. et al. Exp Eye Res 1990:50(1); 65-78.Gerson R.J. et al. Exp Eye Res 1990:50(1); 65-78.Laties A.M. et al. Am J Cardiol 1991:67(6):447-53.Laties A.M. et al. Am J Cardiol 1991:67(6):447-53.Schaefer E.J. N Engl J Med 1998:319:122.Schaefer E.J. N Engl J Med 1998:319:122.Flint O.P. et al. Toxicol AppI Pharmacol 1997; 145(1);99-110.Flint O.P. et al. Toxicol AppI Pharmacol 1997; 145(1);99-110.Avorn J. et al. JAMA 1998; 279 (18):1458-62.Avorn J. et al. JAMA 1998; 279 (18):1458-62.Antonio M. Gotto, Jr, MD, DPhil; Scott M. Grundy, MD, PhD Lowering LDL Cholesterol, Circulation. 1999;99:e4Antonio M. Gotto, Jr, MD, DPhil; Scott M. Grundy, MD, PhD Lowering LDL Cholesterol, Circulation. 1999;99:e4Thompson P.D., Clarkson P., Karas R.H. Statin.associated myopathy. JAMA. 2003 Apr;289(13):1681-90Thompson P.D., Clarkson P., Karas R.H. Statin.associated myopathy. JAMA. 2003 Apr;289(13):1681-90Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous Coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3259–61.Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous Coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3259–61.Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM. Effects of Fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol ele. vations (Lipoprotein and coronary atherosclerosis study ([LCAS]). Am.J.Cardiol. 1997; 80:278–286.Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM. Effects of Fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol ele. vations (Lipoprotein and coronary atherosclerosis study ([LCAS]). Am.J.Cardiol. 1997; 80:278–286.Сусеков АВ, Зубарева МЮ, Рожкова ТА, Кухарчук ВВ. Лескол и коронарный атеросклероз: по результатам трех контролируемых исследований (LCAS, FLARE, LIPS). Международный медицинский журнал 2002; 5(3):225–233.Сусеков АВ, Зубарева МЮ, Рожкова ТА, Кухарчук ВВ. Лескол и коронарный атеросклероз: по результатам трех контролируемых исследований (LCAS, FLARE, LIPS). Международный медицинский журнал 2002; 5(3):225–233.Benghozi R; Bortolini M; Jia Y; Isaacsohn JL; Troendle AJ; Gonasun L Novartis Pharma LTD, Basel, Switzerland. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002 Jan 15; 89(2):231–3.Benghozi R; Bortolini M; Jia Y; Isaacsohn JL; Troendle AJ; Gonasun L Novartis Pharma LTD, Basel, Switzerland. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002 Jan 15; 89(2):231–3.Ballantyne CM; Pazzucconi F; Pinto X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT - Efficacy and tolerability of fluvastatin extended–release delivery system: a pooled analysis. Clin. Ther. 2001 Feb;23(2): 177–92.Ballantyne CM; Pazzucconi F; Pinto X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT - Efficacy and tolerability of fluvastatin extended–release delivery system: a pooled analysis. Clin. Ther. 2001 Feb;23(2): 177–92.
The authors declare that there are no conflicts of interest present.